Relationship between Serum Trough Concentrations of Cibenzoline and Fasting Blood Glucose Levels in Inpatiens Received Cibenzoline Therapy.

Ueno, K.; Morii, Megumi; Ishida, Susumu; Tamamura, Akira; Matsumoto, Kana; Oda, Ayumi; Takada, Mitsutaka; Kamakura, Shiro; Shibakawa, Masahiko

doi:10.5649/jjphcs1975.26.304

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the toxic range of cibenzoline is not clear, it is known that some patients with serum concentration of over 800 ng/ml develop adverse eects, including hypoglycemia. It has also been reported that FBS levels decrease together with an increase of serum trough levels of cibenzoline [14]. However, some reports suggested that a trough level of approximately 200± 400 ng/ml was required to obtain clinical eects and to prevent adverse eects [12,13].…”

Section: Discussionmentioning

confidence: 96%

Efficacy of therapeutic drug monitoring in prevention of hypoglycemia caused by cibenzoline

Takada

Shibakawa

2001

Eur J Clin Pharmacol

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 96%

Efficacy of therapeutic drug monitoring in prevention of hypoglycemia caused by cibenzoline

Takada

Shibakawa

2001

Eur J Clin Pharmacol

Self Cite

View full text Add to dashboard Cite

show abstract

Pharmacodynamics of Cibenzoline-Induced Hypoglycemia in Rats

Takahashi

Ishiwata

Kojima

et al. 2011

Drug Metabolism and Pharmacokinetics

View full text Add to dashboard Cite

Hypoglycemia is one of the serious adverse effects induced by cibenzoline (CBZ), an antiarrhythmic agent. In order to clarify the pharmacodynamics of CBZ-induced hypoglycemia, CBZ was administered intravenously to conscious rats at a dose of 5, 10 or 20 mg/kg and serum samples were collected periodically to determine the concentrations of CBZ, insulin and glucose. The pharmacokinetics of CBZ showed nonlinear characteristics and could be described by a two-compartment model with Michaelis-Menten elimination kinetics. CBZ induced a rapid increase in the serum concentration of insulin. As the CBZ dose was increased, a greater hypoglycemic effect occurred. The indirect response model was applied to account for the CBZ-induced increase in insulin secretion and the subsequent decrease in serum glucose. A linear relationship was assumed between the serum concentration of CBZ and its stimulating effect on insulin secretion. A nonlinear relationship was assumed between the serum concentration of insulin and its stimulating effect on the elimination of serum glucose. The time courses of serum concentrations of CBZ, insulin and glucose after intravenous injection of CBZ could be described by the pharmacokinetic and pharmacodynamic model developed. This approach will be useful for the identification of variable factors related to CBZ-induced hypoglycemia.

show abstract

Relationship between Serum Trough Concentrations of Cibenzoline and Fasting Blood Glucose Levels in Inpatiens Received Cibenzoline Therapy.

Cited by 2 publications

References 0 publications

Efficacy of therapeutic drug monitoring in prevention of hypoglycemia caused by cibenzoline

Efficacy of therapeutic drug monitoring in prevention of hypoglycemia caused by cibenzoline

Pharmacodynamics of Cibenzoline-Induced Hypoglycemia in Rats

Contact Info

Product

Resources

About